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Abstract The gain in knowledge regarding the cellular
mechanisms of T and B lymphocyte activity in the
pathogenesis of Sjögren’s syndrome (SS) and the current
availability of various biological agents (anti-TNF-α, IFN-
α, anti-CD20, and anti-CD22) have resulted in new
strategies for therapeutic intervention. In SS, various phase
I and II studies have been performed to evaluate these new
strategies. Currently, B cell-directed therapies seem to be
more promising than T cell-related therapies. However,
large, randomized, placebo-controlled clinical trials are
needed to confirm the promising results of these early
studies. When performing these trials, special attention has
to be paid to prevent the occasional occurrence of the
severe side effects.
Keywords Sjögren’ssyndrome.Biologicalagent.
Treatment.Monoclonalantibody.Therapy.
Autoimmunedisease
Introduction
Sjögren’s syndrome (SS) is a chronic lymphoproliferative
autoimmune disease with disturbances of T lymphocytes, B
lymphocytes, and exocrine glandular cells [1]. SS can be
primary (pSS) or secondary SS (sSS), the latter being
associated with another autoimmune disease [e.g., rheuma-
toid arthritis, systemic lupus erythematosus (SLE)].
Lymphocytic infiltrates are a characteristic histopatho-
logical finding in SS. These infiltrates consist of T and B
cells. The expression of different cytokines, such as tumor
necrosis factor-α (TNF-α) and interferon-α (IFN-α),
during the formation and proliferation of these infiltrates
has been investigated. There is an overexpression of TNF-
α, which is secreted by CD4+ T lymphocytes, mononuclear
cells, and epithelial cells [2]. The intraglandular synthesis
of TNF-α causes destruction of acini by up-regulation of
Fas at the surface of the glandular epithelial cells,
stimulation of secretion of type 2 and 9 matrix metal-
loproteases by epithelial cells, and overexpression of
different chemokines [3–5]. IFN-α is produced by activated
plasmacytoid dendritic cells in primary SS (pSS), and
numerous IFN-α-producing cells have been detected in
labial salivary glands [6]. IFN-α promotes the autoimmune
process by increasing autoantibody production and through
the formation of endogenous IFN-á inducers. IFNs have
potent immunomodulating properties and are thought to
trigger a systemic biological response [7].
Besides the presence of proinflammatory cytokines,
described in the previous paragraph, recent studies have
shown an important role for B cells in the pathogenesis of
SS. Presence of autoantibodies and hypergammaglobuline-
mia are both considered to reflect B cell hyperactivity.
Systemic complications of SS are associated with this B
cell hyperactivity [8]. Moreover, about 5% of SS patients
develop malignant B cell lymphoma [9]. B cell activating
factor (BAFF), also known as B lymphocyte stimulator
(BLyS), is an important factor in local and systemic
autoimmunity [1]. Dysregulated BAFF expression is impli-
cated in disease progression and perpetuation of humoral
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has been shown to result in B cell proliferation and
antibody production resulting in inflammation and destruc-
tion of the salivary glands, as well as kidney failure similar
to observations seen in SLE [10]. In humans, circulating
BAFF levels are increased in patients with pSS and
correlate with disease activity [11].
Recent insights in the cellular mechanisms of T and B
lymphocyte activity in the pathogenesis of SS and the
current availability of various biological agents have
resulted in new strategies for therapeutic intervention. The
use of these biological agents in the treatment of SS will be
discussed in this review.
Biological Agents
Currently, biological agents have been introduced in
various systemic autoimmune diseases, as rheumatoid
arthritis and SLE. Biological agents most frequently applied
in autoimmune diseases are monoclonal antibodies, soluble
receptors, and molecular imitators [12]. These biological
agents enhance or replace conventional immunosuppressive
therapy. In contrast to rheumatoid arthritis and SLE, no
biological agent has been approved yet for the treatment of
SS, but several phase II and III studies have been or are
currently conducted. The biological agents used in SS trials
are IFN-α and agents targeting TNF-α and B cells (anti-
CD20, anti-CD22). Although no trials have been performed
yet with BAFF antagonists, this might be a promising
therapy [13] and will be discussed in this review, as well.
Anti-TNF-α Monoclonal Antibodies
There are three main biological agents targeting TNF-α: the
chimeric monoclonal IgG1 antibody infliximab, the recep-
tor fusion protein etanercept, and the fully humanized
monoclonal antibody adalimumab.
In an open-label study, short-term treatment with
infliximab was reported to be very effective in active pSS
over a 3-month period [14]. Sixteen patients received three
infusions (3 mg/kg) at weeks 0, 2, and 6, which led to
significant improvement in all clinical and functional
parameters, including global assessments, erythrocyte sed-
imentation rate, whole salivary flow rate, tear secretion
(Schirmer test), tender joint count, fatigue score, and
sensation of dry eyes and dry mouth. Three patients, all
with short disease duration (<3 years), were considered to
be in complete remission up till 1 year. In 10 out of the 16
patients, SS symptoms, particularly mouth dryness, re-
lapsed after a median of 9 weeks. In a follow-up study, a
maintenance regimen of one infusion every 12 weeks was
evaluated in these 10 patients. Retreatment induced an
improvement of signs related to SS that was comparable
with the effects from the three loading infusions [15]. To
confirm these promising results from an uncontrolled study,
the Trial of Remicade In Primary Sjögren’s Syndrome study
was designed. In this multicenter, double-blinded, placebo-
controlled, randomized clinical trial, 103 patients with
active pSS were included and treated with infliximab infu-
sions (5 mg/kg) or placebo at weeks 0, 2, and 6. Follow-up
was 22 weeks. Primary endpoint was an improvement of
>30% of two of three VAS scores measuring joint pain,
fatigue, and dry eyes. There were several secondary
endpoints of which one was the basal salivary flow rate. In
contrast tothepreviously mentioned uncontrolledstudies,no
evidence of efficacy of infliximab treatment on all clinical
and functional parameters could be demonstrated in this
randomized controlled clinical trial [2].
A trial on 15 pSS patients (mean disease duration
3.6 years) with 25-mg etanercept, subcutaneously twice a
week for 12 weeks, did not reveal a reduction in sicca
symptoms and signs, neither did the repeated treatment for
up to 26 weeks. Only in the subset of four patients with
severe fatigue a decrease in fatigue was observed [16].
Another trial evaluating subcutaneous administration of
etanercept vs placebo for 12 weeks (28 patients) also
showed no clinical efficacy [17]. No trials of adalimumab
treatment in pSS have been reported in the literature yet.
Inconclusion,TNF-targetingtreatment couldnotbe proven
to be of benefit in reducing the complaints of pSS patients.
IFN-α
IFNs are proteins with antiviral activity and potent immuno-
modulating properties. SS patients have an activated type I
IFN system [6]. Such a role for IFN-α appears to contradict
the reports described below, that low doses of IFN-α
administered via the oromucosal route increase the unstimu-
lated salivary output. However, it is hypothesized that oral
IFN-α treatment may act by increasing saliva secretion by
up-regulation of aquaporin 5 transcription without signifi-
cantly influencing the underlying autoimmune process [6, 7].
In a phase II study, treatment of pSS patients with IFN-α
administered via the oromucosal route (by dissolving
lozenges) was demonstrated to be effective (improvement
of salivary output, decreased complaints of xerostomia) and
safe [18]. Based on these promising results, a randomized,
parallel group, double-blinded, placebo-controlled clinical
trial (497 pSS patients) was designed. Patients were
randomized into two groups and received a 24-week daily
treatment with either 450 IU IFN-α (150 IU three times
per day) or placebo in a ratio 3:2, administered by the
oromucosal route. This randomized, controlled clinical trial
failed to demonstrate a significant effect on the primary
endpoints (VAS score for oral dryness and stimulated whole
Clinic Rev Allerg Immunol (2007) 32:292–297 293 293salivary flow) in the IFN-α group relative to the placebo
group. There was a significant increase in unstimulated
whole saliva in the patients treated with IFN-α, which
correlated positively and significantly with improvement in
seven of eight symptoms associated with oral and ocular
dryness. No adverse events were observed [7].
In conclusion,no clinical evidence for the efficacy of IFN-
α treatment in pSS patients has been shown yet; however,
an improvement of unstimulated whole saliva was observed.
Further research is needed to objectify the effect of IFN-á on
salivary gland tissue.
Anti-CD20 Monoclonal Antibodies
Anti-CD20 (rituximab) is a chimeric humanized monoclonal
antibody specific for the B cell surface molecule CD20,
which is expressed on the surface of normal and malignant
pre-B and mature B lymphocytes. CD20 mediates B cell
proliferation and differentiation. This antibody has been
demonstrated to prevent B cells from proliferating and to
induce lysis of B cells by complement-dependent and anti-
body-dependent cytotoxicitymechanismsaswellasbydirect
induction of apoptosis [19].
Rituximabis currently usedfor thetreatment of low-grade
B cell lymphomas [20]. In controlled studies, it was shown
to be safe and effective in the treatment of rheumatoid arthritis
[21–23]. Moreover, open-label studies in SLE patients are
promising [24].
In an open-label phase II study, 15 patients with pSS
were treated with 4 infusions of rituximab (375 mg/m
2 once
weekly) and followed up for a 3-month period. Eight of the
15 patients were early pSS patients (mean disease duration
28 months, all had residual salivary gland function at
baseline), and 7 patients had a concomitant mucosa-
associated lymphoid tissue (MALT) lymphoma (mean
disease duration 79 months).
In the early pSS patients, rituximab treatment resulted in
significant improvement of subjective symptoms and an
increase in salivary gland function. All patients showed a
rapid depletion of peripheral B cells within a few weeks,
accompanied by a decrease in IgM-RF levels [8]. Repeated
parotid gland biopsies in five of the early patients after
treatment showed redifferentation of the lymphoepithelial
duct lesions into normal striated ducts, possibly indicating
regeneration of salivary gland tissue (unpublished data).
Five of the eight pSS patients without a MALT lymphoma
received a second course of rituximab (after 9–11 months) due
to recurrence of symptoms. Retreatment resulted in the same
significantimprovementofthesalivaryflowrateandsubjective
symptoms compared to the results of the first treatment,
together with a decrease in B cells and IgM-RF levels.
Six of the seven MALT/pSS patients were initially
effectively treated with rituximab. The remaining MALT/
pSS patient had progressive MALT disease and severe
extraglandular SS disease within 3 months after the start of
rituximab treatment. Cyclophosphamide was added, which
led to stable disease of both MALT and SS. One of the six
patients initially responding had a recurrence of MALT
lymphoma after 9 months and was successfully retreated
with rituximab. The other patients are still in remission
(unpublished data).
In another open-label study, 16 pSS patients received
only two weekly rituximab infusions (375 mg/m
2), with a
follow-up of 36 weeks. Again, treatment resulted in rapid
complete depletion of peripheral B cells. At week 12, a
significant improvement of VAS scores for fatigue and
dryness was recorded, and at week 36, a significant
improvement for VAS scores for global disease, fatigue,
dry mouth, dry eyes, and dry vagina, but also in the number
of tender joint and tender joint counts was seen [25]. Both
in the study of Pijpe et al. [8] and the study of Devauchelle-
Pensec et al. [25], patients with a short disease duration
showed more improvements than patients with longer
disease duration.
Two trials retrospectively evaluated the effect of ritux-
imab (four infusions of 375 mg/m
2) in 18 pSS patients
(mean disease duration 10 years) with systemic features.
Self-reported dryness improved in six patients (VAS scores
not known for three patients, no improvement in the other
nine patients). Both studies reported good efficacy of the
treatment on systemic features [26, 27].
In conclusion, in phase II trials, it has been shown that
rituximab seems to be effective for at least 6–9 months in
pSS patients with active disease, improving both subjective
and objective complaints. Retreatment with rituximab
resulted in a similar good clinical response. In pSS patients
with longer disease duration, without residual salivary
gland function, rituximab treatment seems to be effective
for systemic features. To confirm these promising results,
randomized placebo-controlled clinical trials are needed.
Anti-CD22 Monoclonal Antibodies
Epratuzumab is a fully humanized monoclonal antibody
specific for the B cell surface molecule CD22. CD22 is
expressed on the surface of normal mature and malignant B
lymphocytes. CD22 appears to be involved in the regula-
tion of B cell activation through B cell receptor signaling
and cell adhesion [28]. In an open-label phase I/II study,
safety and efficacy of epratuzumab were investigated in 16
pSS patients. Follow-up was 6 months. These pSS patients
received four doses of 360 mg/m
2 epratuzumab intrave-
nously. Mean disease duration before therapy was 2.9 years,
and none of the patients had received prior B cell-targeted
therapy. Most improvements occurred in the Schirmer test,
unstimulated whole salivary flow and the VAS score for
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Clinic Rev Allerg Immunol (2007) 32:292–297 295 295fatigue. The new developed disease activity score consisted
of the four domains: dryness of the eyes, dryness of the
mouth, fatigue, and laboratory parameters. Based on this
score, 53% achieved at least 20% improvement in at least
two domains at 6 weeks. Corresponding rates for 10, 18,
and 32 weeks are 53, 47, and 67%. Remarkably, the
number of responders was higher 6 months after the
treatment administration than earlier. Peripheral B cells
decreased with a median decrease of 54 and 39% at 6 and
18 weeks, respectively.
In conclusion, epratuzumab seems to be an effective
treatment. Randomized, placebo-controlled clinical trials
are needed before epratuzumab can be advised for general
treatment in pSS patients [29].
Anti-BAFF
BAFF is a B cell-activating factor that acts as a positive
regulator of B cell function and expansion. BAFF levels
were found elevated in serum and saliva in SS patients, but
no correlation could be shown between serum and saliva
levels [30]. However, circulating levels of BAFF in pSS
patients were shown to be a marker for disease activity [11].
To the best of our knowledge, no trials have been
performed with anti-BAFF treatment in SS yet, but such an
approach might be considered for future trials. Currently,
two human BAFF antagonists have been developed, a
human antibody (anti-BLyS) that binds to soluble BAFF
and a fusion protein of one of the BAFF receptors [31, 32].
Especially, SS patients with elevated BAFF levels, hyper-
gammaglobulinemia, elevated levels of autoantibodies, and
associated B cell lymphoma might be candidates for anti-
BAFF treatment [33].
Safety and Tolerability of Biological Agents
The most important side effects of treatment with biological
agents are direct mild infusion reactions. Several patients
developed a serum sickness-like disease a few days after the
second infusion that might be related to the formation of
antibodies against the biological agent [human anti-chimeric
antibodies (HACAs) or human anti-human antibodies]. A
few patients developed infections during treatment with a
biological agent; however, some patients concomitantly
used other immunosuppressive therapies. Therefore, the
direct relation between the biological agent and the
infection is unsure. All adverse events reported in the trials
described in this review are reported in Table 1. According
to this table, the most frequent side effects of treatment with
biological agents are mild infusion reactions. The most
severe side effect of the various treatments used in SS
patients was the development of a serum sickness-like
disease. This adverse effect of treatment occurred in 16% (8
of 49) of the patients treated with rituximab. HACA
formation was observed in patients developing a serum
sickness-like disease and occurred only in patients receiv-
ing low-dose corticosteroids and no other immunosuppres-
sive drugs. It is assumed that higher doses of corticosteroids
during treatment might prevent the occurrence of serum
sickness.
Future Perspectives
Biological agents are promising therapies for SS. Random-
ized studies failed to show a clinical effect of anti-TNF-α
and IFN-α in the treatment of SS. Notwithstanding the
unfortunate results of anti-TNF-α and IFN-α, B cell
depletion (both anti-CD20 and anti-CD22) seems very
promising. Again, this promising effect, as was previously
also assumed for anti-TNF-α and IFN-α, must be con-
firmed in larger randomized controlled clinical trials.
HACAs have been reported to occur at a higher rate in
patients with an autoimmune disease. It seems that
monoclonal antibodies are more immunogenic in active
autoimmune disease, independent of the type of disease.
Additional use of immunosuppressive therapy in these
patients might be mandatory to prevent serious side effects.
These unwanted side effects might also be prevented by the
use of fully humanized antibodies. The currently available
humanized antibodies are promising, but need further study.
Moreover, there is still a need for improved assessment
parameters to monitor treatment effects, both subjectively
and objectively. For studies on intervention of SS,
evaluation of the parotid gland might be of use because
function, composition of saliva, and histology can be eval-
uated on the same gland at different time points. Activity
scores are currently under development by Bowman and
Vitali [34, 35]. Finally, as soon as effective intervention
treatments have been established, the cost-effectiveness of
these currently very expensive antibodies needs to be
analyzed to select those patients that might benefit the
most from this kind of treatment.
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